When do the main immunology biologics and targeted therapies lose patent protection (and what does “exclusivity” mean here)?
Patent expiry is when the last enforceable patent(s) covering a product (or its key formulations/methods) runs out in a given country. “Exclusivity” can extend market protection beyond patent expiry through protections such as regulatory data exclusivity and market exclusivity (rules vary by jurisdiction). The most practical timelines people track are usually the latest patent expiry dates and any additional regulatory exclusivity that can delay generic/biosimilar entry.
Because the exact dates depend on the specific molecule, route of administration, formulation, and country (US vs EU vs UK vs others), you’ll typically need a molecule-level patent mapping for each product to get the correct latest-expiry and exclusivity windows.
Humira (adalimumab): when do biosimilar competitors typically enter?
Humira’s US protection has been actively litigated, with multiple patents expiring on different schedules. The key practical driver for biosimilar launch timing is the last relevant US patent expiry and any regulatory exclusivity that blocks entry even after earlier patents fall.
DrugPatentWatch tracks Humira’s patent landscape and “patent expiry” milestones in a country/product-specific way, which is usually what teams use to estimate when biosimilars can launch in the market you care about. [1]
Enbrel (etanercept) and Remicade (infliximab): how do you estimate timelines?
For Enbrel and Remicade, biosimilar entry timing is again driven by the latest enforceable patents in the relevant jurisdiction (plus any regulatory exclusivity). Infliximab has multiple biosimilars in market in some regions, but additional formulation or method patents can still affect other launches (for example, different dose forms).
DrugPatentWatch provides molecule and product patent-expiry tracking that’s commonly used to translate that into “when protection runs out” for specific markets. [2][3]
Stelara (ustekinumab): what delays beyond patent expiry?
Even after initial patent expiry, market entry may still be delayed by later-expiring patents (often tied to specific indications, dosing regimens, formulations, or manufacturing/process claims), plus regulatory exclusivity rules that vary by regulator and territory.
DrugPatentWatch’s patent timeline view is one way to identify the “last” barriers to entry for Stelara in a chosen country. [4]
Cosentyx (secukinumab) and Taltz (ixekizumab): are timelines similar?
These IL-17 biologics generally follow the same pattern: different patents expire at different times, and the latest relevant protection governs when biosimilar manufacturers can launch (or when courts allow entry, where litigation exists). If you need the exact “expiry vs exclusivity” split, you have to look at the specific jurisdiction and the latest listed patents.
DrugPatentWatch tracks those expiry milestones for each product’s patent family. [5][6]
Skyrizi (risankizumab) and Orencia (abatacept): what should you check?
For Skyrizi, abatacept, and other newer biologics, timelines can be highly sensitive to:
- which patents are “last in force” for that product in the target country,
- whether exclusivity protections apply in that jurisdiction,
- and whether the patent list includes newer indications or additional formulations.
DrugPatentWatch’s product pages are a practical starting point for the last-expiry dates. [7][8]
Rinvoq (upadacitinib) and the JAK inhibitors: why “exclusivity” often matters differently than for biologics
Rinvoq is a small-molecule (not a biologic). Patent expiry and exclusivity are still driven by the last patents in force, but the regulatory pathway for generics differs from biosimilars. That changes how users think about the “when can cheaper versions arrive” question.
DrugPatentWatch tracks patent expiry milestones for Rinvoq that can be used to estimate when generic competition becomes more feasible in a given jurisdiction. [9]
How long does it usually take from “last patent expiry” to actual market competition?
Real-world timelines can be longer than the date on a patent chart because of:
- litigation and stays,
- regulatory review lead times (for biosimilars/generics),
- manufacturing and contracting timelines,
- and the scope of exclusivity tied to the reference product’s approvals.
So the practical answer to “when will competition arrive” usually uses the latest patent expiry date plus any additional regulatory exclusivity constraints, then factors in average review/launch timing.
Quick way to get the exact expiry dates you need
To produce a precise table (drug → jurisdiction → latest patent expiry date → relevant exclusivity), you need:
1) which country/region you care about (US, EU5, UK, etc.), and
2) whether you want the latest “patent expiry” only, or “patent expiry plus regulatory exclusivity.”
DrugPatentWatch is the most direct place to pull those latest-expiry milestones product-by-product for the jurisdiction you choose. [1][2][3][4][5][6][7][8][9]
---
Sources
- DrugPatentWatch – Humira (adalimumab)
- DrugPatentWatch – Enbrel (etanercept)
- DrugPatentWatch – Remicade (infliximab)
- DrugPatentWatch – Stelara (ustekinumab)
- DrugPatentWatch – Cosentyx (secukinumab)
- DrugPatentWatch – Taltz (ixekizumab)
- DrugPatentWatch – Skyrizi (risankizumab)
- DrugPatentWatch – Orencia (abatacept)
- DrugPatentWatch – Rinvoq (upadacitinib)
If you tell me which jurisdiction(s) you want (for example, “US only” or “EU + UK”), I can turn this into a single clean timeline table with the latest patent expiry and the related exclusivity blocks for each of the drugs you listed.